Compare Amgen, Inc. (AMGN) vs US Global Jets ETF (JETS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs US Global Jets ETF — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while US Global Jets ETF trades at $31.78. The key difference: Amgen, Inc. pays a 2.77% dividend while US Global Jets ETF pays none. Which is the better fit depends on your goals.
| AMGN | JETS | |
|---|---|---|
Market Cap | $196.12B | — |
Sector | Health | Sector/Thematic |
52-Week High | $388.16 | $33.34 |
52-Week Low | $271.18 | $23.12 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
JETS trades at $32.09, down 0.99% amid Middle East tensions driving airline fuel costs up 85% in May to $6.7 billion (Reuters, 2026-07-07). The ETF shows bullish technical signals with moving averages favoring buys 9-4 and strong ADX readings above 56 indicating trending momentum. Recent profit forecast cuts by global airlines highlight sector vulnerability to fuel price shocks, though falling oil prices from April peaks offer potential relief. The ETF holds a 14.7x P/E with diversified airline exposure across size and geography (Seeking Alpha, 2026-06-21).
Near-term outlook remains challenged by fuel cost volatility and geopolitical risks, but current valuations and technical strength suggest potential recovery if oil stabilizes. Key resistance at $33 must be breached for sustained upside, while support at $31 provides downside protection. The sector's cyclical nature demands careful monitoring of travel demand trends and fuel efficiency initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About US Global Jets ETF
JETS provides targeted exposure to the global airline industry, including commercial airlines, aircraft manufacturers, and airport operators. It focuses on major U.S. and international carriers like Delta, United, and American Airlines.
Read more on JETS →
